Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

Abstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marina G. Birck, Jessica Boivin, Laura Yan, Nathalie Carrier, Cristiano S. Moura, Walter P. Maksymowych, Gilles Boire, Denis Choquette, Luck Lukusa, Michael Mallinson, Linda Wilhelm, Autumn Neville, Sasha Bernatsky
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-07-01
Col·lecció:	Arthritis Research & Therapy
Matèries:	Rheumatoid arthritis Etanercept Remission induction Biosimilar pharmaceuticals
Accés en línia:	https://doi.org/10.1186/s13075-025-03607-7
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!